Business Development Containment Contract Manufacturing FDA Approval 
The Pharma Data
NOVEMBER 5, 2020
FDA accepted for priority review Libtayo ® (cemiplimab-rwlc) for both advanced non-small cell lung cancer and basal cell carcinoma. FDA approved Inmazeb for Ebola ( Zaire ebolavirus). NASDAQ: REGN ) today announced financial results for the third quarter of 2020 and provided a business update. government. 30%. *. *.
The Pharma Data
MAY 4, 2021
Pfizer’s Meridian subsidiary, the manufacturer of EpiPen and other auto-injector products, which had been reported within the results of the Upjohn Business (4) in the first three quarters of 2020 , is now included within the Hospital therapeutic area for all periods presented. Hospital products, which grew 10% operationally to $2.3
Expert insights. Personalized for you.
52 
Let's personalize your content